Truist Securities Initiates Coverage of Summit Therapeutics

Truist Securities Initiates Coverage Of Summit Therapeutics

1 week from now

As of December 23, 2024, the average one-year price target for Summit Therapeutics is $34.00/share. The forecasts range from a low of $23.23 to a high of $46.20. The forecasts …

nasdaq.com

Summit Therapeutics Initiated With A Buy At Truist

1 week from now

Jan 8, 2025  · Truist initiated coverage of Summit Therapeutics with a Buy rating and $35 price target Summit is a biotech company built around ivonescimab, the most clinically advanced …

businessinsider.com

Truist Starts Summit Therapeutics With Buy Rating On Ivonescimab ...

1 week from now

Jan 8, 2025  · On Wednesday, Truist Securities initiated coverage on Summit Therapeutics plc (NASDAQ: SMMT) stock, assigning a Buy rating and setting a price target of $35.00. The …

investing.com

Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated By

1 week from now

Jan 8, 2025  · HC Wainwright reaffirmed a "buy" rating and set a $44.00 price target on shares of Summit Therapeutics in a research note on Monday, November 18th. Jefferies Financial …

marketbeat.com

Truist Securities Initiates Coverage Of Summit Therapeutics (SMMT …

1 week from now

Analyst Price Forecast Suggests 80.71% Upside As of December 23, 2024, the average one-year price target for Summit Therapeutics is $34.00/share. The forecasts range from a low of …

msn.com

Truist Starts Summit Therapeutics With Buy Rating On Ivonescimab ...

1 week from now

Jan 8, 2025  · On Wednesday, Truist Securities initiated coverage on Summit Therapeutics plc (NASDAQ: SMMT) stock, assigning a Buy rating and setting a price target of $35.00.The firm’s …

investing.com

Truist Initiates Summit Therapeutics At Buy With $35 Price Target

1 week from now

Jan 8, 2025  · Truist Initiates Summit Therapeutics at Buy With $35 Price Target January 08, 2025 at 06:32 am EST Share This article is reserved for members . To unlock the article, …

marketscreener.com

Summit Therapeutics (NASDAQ:SMMT) Research Coverage Started …

1 week from now

6 days ago  · Citigroup lowered Summit Therapeutics from a “buy” rating to a “neutral” rating and raised their target price for the company from $19.00 to $23.00 in a report on Friday, …

etfdailynews.com

Summit Therapeutics Shares Jump Following Truist's 'buy' Rating …

1 week from now

Jan 8, 2025  · Shares of Summit Therapeutics (NASDAQ:SMMT), a drug development company, have seen a boost of approximately 4%, reaching $18.88.. This surge follows Truist Securities …

grafa.com

Summit Therapeutics Rises After Truist Starts Coverage With 'buy ...

1 week from now

Jan 8, 2025  · ** Shares of drug developer Summit Therapeutics NASDAQ:SMMT rise ~4% to $18.88** Brokerage Truist Securities starts coverage on SMMT with "buy" rating; PT $35** PT …

tradingview.com

Why Summit Therapeutics Rocketed 584% In 2024 | The Motley Fool

1 week from now

2 days ago  · But in early 2025, Wall Street remains bullish, with Truist analyst Asthika Goonewardene recently giving the stock a buy rating and $35 price target, predicting …

fool.com

Truist Initiates Summit Therapeutics At Buy With $35 Price Target

1 week from now

Jan 7, 2025  · -- Summit Therapeutics has an average rating of buy and mean price target of $33.33, according to analysts polled by FactSet. ...-- Summit Therapeutics has an average …

marketscreener.com

Why Summit Therapeutics Rocketed 584% In 2024 - Yahoo Finance

1 week from now

1 day ago  · Shares of biotech Summit Therapeutics (NASDAQ: SMMT) skyrocketed 583.7% in 2024, according to data from S&P Global Market Intelligence. ... giving the stock a buy rating …

yahoo.com

Truist Initiates Summit Therapeutics With Buy Rating And $35 Price …

1 week from now

Jan 9, 2025  · The firm sees a broader total addressable market for ivonescimab, making Summit a potential takeover target for large biopharma companies. Summit Therapeutics (NASDAQ: …

ainvest.com

Truist Starts Summit Therapeutics With Buy Rating On Ivonescimab ...

1 week from now

Jan 8, 2025  · On Wednesday, Truist Securities initiated coverage on Summit Therapeutics plc (NASDAQ: SMMT) stock, assigning a Buy rating and setting a price target of $35.00.The firm's …

investing.com

Truist Initiates Summit Therapeutics At Buy With $35 Price Target

1 week from now

Jan 8, 2025  · -- Summit Therapeutics has an average rating of buy and mean price target of $33.33, according to analysts polled by FactSet. ...

marketscreener.com

24,879 Shares In Summit Therapeutics Inc. (NASDAQ:SMMT

1 week from now

13 hours ago  · Stifel Nicolaus lifted their price target on shares of Summit Therapeutics from $25.00 to $40.00 and gave the stock a "buy" rating in a report on Wednesday, September …

marketbeat.com

Summit Therapeutics Reports Inducement Grants Under Nasdaq …

1 week from now

1 day ago  · Truist Initiates Summit Therapeutics at Buy With $35 Price Target MT Summary ... Truist Initiates Summit Therapeutics at Buy With $35 Price Target ... Dec. 11: MT Jefferies …

marketscreener.com

SMMT - Stock Quotes For SMMT Ent Holdg, NASDAQ: SMMT …

1 week from now

Merck rival Summit draws new buy from Truist on deal prospects ... Benzinga · 2d ago. Summit Therapeutics Price Target Announced at $35.00/Share by Truist Securities. Dow Jones · 2d ago. Summit Therapeutics initiated with a Buy at Truist. TipRanks · 2d ago. SUMMIT THERAPEUTICS INC <SMMT.O>: TRUIST SECURITIES INITIATES COVERAGE WITH BUY ...

webull.com

Truist Securities Initiates Coverage On Summit Therapeutics With …

1 week from now

Jan 8, 2025  · Truist Securities analyst Asthika Goonewardene initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy rating and announces Price Target of $35.

sahmcapital.com

Summit Therapeutics Shares Are Trading Higher After Truist …

1 week from now

Jan 8, 2025  · Summit Therapeutics shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and a $35 price target.

sahmcapital.com